Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
NCI-Sponsored Multi-Disciplinary Study for MR Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-Grade Brain Tumors and/or Cerebral Metastases
Sponsor: National Cancer Institute (NCI)
This NA trial investigates Central Nervous System Lymphoma and Malignant Glioma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 9 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2022 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2021 — Jul 2022 [monthly]
Unknown Status NA
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Aug 2018 — Jul 2020 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Portland, United States